Alzheimer's Disease: Archives News of the month
Preclinical Alzheimer Disease pathology in studies of memory and aging
Alzheimer's Disease 1 min.
Alzheimer's Disease
1 min.
Published on 02/04/2025 |
Original article (Abstract)
| Nicole S.
McKay
et al. | Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; 20(S2): 093516
Aryloxypropanolamine mitigates Alzheimer‐like phenotype by directly removing amyloid aggregates
Alzheimer's Disease 1 min.
Alzheimer's Disease
1 min.
Published on 26/03/2025 |
Original article (Abstract)
| Soljee
Yoon
et al. | Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; 20(S6): 088498
The accumulation of amyloidogenic proteins is recognized as a primary biomarker, initiator of pathology, and a potential therapeutic target for Alzheimer’s disease (AD). An unbiased screening of a small molecule library was conducted to identify new chemical compounds exhibiting amyloid‐dissociative...
Preclinical Alzheimer Disease pathology in studies of memory and aging
Alzheimer's Disease 1 min.
Alzheimer's Disease
1 min.
Published on 19/03/2025 |
Original article (Abstract)
| Nicole S.
McKay
et al. | Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; 20(S9): 094151
Pragmatic considerations in clinical biomarker testing for Alzheimer disease
Alzheimer's Disease 1 min.
Alzheimer's Disease
1 min.
Published on 12/03/2025 |
Original article (Abstract)
| Suzanne E.
Schindler
et al. | Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; 20(S2): 088362
Development of tau targeted protein degraders for Alzheimer disease
Alzheimer's Disease 1 min.
Alzheimer's Disease
1 min.
Published on 05/03/2025 |
Original article (Abstract)
| Lisha
Wang
et al. | Alzheimer's & dementia : the journal of the Alzheimer's Association 2024; 20(S6): 086380
Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti‐amyloid antibodies aducanumab and lecanemab have been approved by the US Food and...
